Current Positions:

• 2020 - Heart Foundation Future Leader Fellow; School of Biomedical Sciences and Medical School, UWA
• 2013 - Invited Visiting Researcher; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University

Previous Positions:

• 2005 Teaching Intern; School of Medicine and Pharmacology, UWA
• 2007 Unilever Postdoctoral Fellow; School of Medicine and Pharmacology, UWA; Unilever Colworth, UK
• 2008 – 2009 National Heart Foundation Postdoctoral Research Fellow; School of Medicine and Pharmacology, UWA
• 2008 – 2010 Development and Communication of Research Course Controller, UWA
• 2008 – 2010 Masters of Clinical Research Coordinator, UWA
• 2010 A & A Saw Medical Research Fellowship, UWA
• 2010 – 2012 Visiting Postdoctoral Research Fellow, Jean Mayer USDA Human Nutrition Research Center on Ageing, Tufts University, Boston MA, USA
• 2010 – 2012 Visiting Postdoctoral Research Fellow, Department of Nutrition, Harvard University, Boston MA, USA
• 2010 – 2014 National Health and Medical Research Council (NHMRC) CJ Martin Early Career Fellow; School of Medicine and Pharmacology, UWA
• 2015 – 2020 Heart Foundation Future Leader Fellow; School of Medicine and Pharmacology, UWA

Funding:

NHMRC

• Reducing cardiovascular risk in the metabolic syndrome and type 2 diabetes: novel approaches to studies of lipoprotein metabolism; NHMRC Project Grant ($527,275; 2008-9) [AI]
• Novel approaches to studies of lipoprotein metabolism; NHMRC training fellowship ($336,170; 2010-2014) [CIA]
• Niacin reduces Lp(a) in type 2 diabetes; NHMRC Project Grant ($354,920; 2012-14) [CID]
• Lipoprotein(a) metabolism in subjects at high risk of cardiovascular disease; NHMRC Project Grant ($668,434; 2014-16) [CIA]

Heart Foundation of Australia

• Coordinated regulation and function of apoC-III in obesity; NHF Grant-In-Aid ($98,788; 2008-9) [AI]
• National Heart Foundation Postdoctoral Fellowship ($131,500; 2008-9) [CIA]
• ApoC-III as a regulator of fatty acid and lipoprotein metabolism in women: understanding dyslipidemia as a cardiovascular risk factor; NHF Grant-In-Aid ($127,404; 2008-9) [CIC]                                      
• Pathophysiology and Therapeutic Regulation of Lipid Disorders in Subjects at High Cardiovascular Disease Risk; NHF Future Leader Fellowships (2015-2018) [CIA]

Raine Medical Research Foundation

• A systems biology approach to study the coordinate regulation and function of apolipoprotein C-III in the metabolic syndrome; Raine Priming Grant ($183,361; 2008-9) [CIA]

University of Western Australia

• A & A Saw Medical Research Fellowship ($145,074; 2010-11)[CIA]
• Kinetic Defects in Lipoprotein Metabolism in Patients with Chronic Renal Failure; UWA Research Grant (A$27,600; 2008) [CIA]

Royal Perth Hospital Medical Research Foundation

• ApoC-II as a regulator of fatty acid and lipoprotein metabolism in women: understanding dyslipidemia as a cardiovascular risk factor, Medical Research Foundation Grant ($16,500; 2013) [CIA]

SCGOPHCG RAC

• The link between donor-specific anti-human leukocyte antigen (HLA) antibody and cardiac events in kidney and kidney-pancreas transplant patients ($ 29,970.10) [PI2]

Dr Esther Ooi is a Heart Foundation Future Leader Fellow at the University of Western Australia (UWA) with a research program focused on identifying, testing and validating new and lifelong risk factor exposures in predicting risk across cardiovascular and metabolic diseases using classical and genetic epidemiological designs. She received her research training at UWA (2003-2007), graduating with Distinction and undertook her postdoctoral fellowship at Tufts and Harvard Universities (Boston, MA 2010-2012) supported by an NHMRC CJ Martin Fellowship. She has obtained NHMRC project grant funding, continuous career fellowships and other grants and is actively engaged in peer review processes. She continues to contribute to postgraduate and undergraduate student teaching, supervision and training. She is also a member of the UWA Gender Equity Working Group.